Stock Price Movement and Market Context
On 9 Mar 2026, Procter & Gamble Health Ltd’s shares declined by 2.04% intraday, hitting the low of Rs.4781, which is the lowest level recorded in the past year. The stock underperformed its sector by 0.29% on the day, reflecting a broader negative sentiment in the market. The Sensex itself opened with a gap down at 77,056.75, down 1,862.15 points or 2.36%, and was trading at 77,088.10, down 2.32% at the time of reporting. The market has been on a downward trajectory, with the Sensex falling 6.91% over the last three weeks and trading below its 50-day moving average, although the 50DMA remains above the 200DMA.
Procter & Gamble Health Ltd’s stock is currently trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained downward momentum. The stock’s 52-week high was Rs.6700, indicating a substantial decline of approximately 28.7% from that peak.
Financial Performance and Valuation Metrics
Over the past year, the company’s stock has generated a negative return of 9.19%, contrasting with the Sensex’s positive 3.71% gain over the same period. Despite this, the company’s profits have increased by 16.7% in the last year, suggesting some operational resilience amid price pressures.
However, the company’s long-term growth rates have been modest, with net sales growing at an annual rate of 7.63% and operating profit increasing by 8.59% over the last five years. The most recent quarterly results showed a decline in profitability, with Profit Before Tax excluding other income falling by 11.27% to Rs.104.46 crores, and Profit After Tax decreasing by 14.6% to Rs.77.59 crores.
Valuation metrics indicate a relatively expensive stock. The company’s Return on Equity (ROE) stands at a high 47.4%, yet it trades at a Price to Book Value ratio of 13.1, which is elevated compared to typical industry standards. The PEG ratio is 1.7, reflecting a valuation that factors in growth but may be considered stretched given the recent price performance.
At the current price, Procter & Gamble Health Ltd offers a dividend yield of 4.18%, which is attractive relative to many peers in the Pharmaceuticals & Biotechnology sector. This yield reflects the company’s commitment to returning value to shareholders despite the recent price decline.
Just made the cut! This Mid Cap from the Heavy Electrical Equipment sector entered our elite Top 1% list recently. Discover it before the crowd catches on!
- - Top-rated across platform
- - Strong price momentum
- - Near-term growth potential
Comparative Performance and Sector Positioning
Procter & Gamble Health Ltd has underperformed not only the Sensex but also the broader BSE500 index over multiple time frames, including the last three years, one year, and three months. This underperformance highlights challenges in maintaining competitive momentum within the Pharmaceuticals & Biotechnology sector.
Despite the stock’s recent decline, the company maintains a strong management efficiency profile, with a high ROE of 36.14% and a low average debt-to-equity ratio of zero, indicating a conservative capital structure. Institutional investors hold 20.81% of the company’s shares, reflecting confidence from entities with significant analytical resources.
Recent Rating Changes and Market Sentiment
On 7 Jan 2026, the company’s Mojo Grade was downgraded from Hold to Sell, with a current Mojo Score of 37.0. The Market Cap Grade stands at 3, indicating a mid-tier market capitalisation relative to peers. The downgrade reflects concerns over the company’s growth prospects and valuation metrics amid the recent price decline.
Procter & Gamble Health Ltd or something better? Our SwitchER feature analyzes this small-cap Pharmaceuticals & Biotechnology stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
Sector and Market Environment
The Pharmaceuticals & Biotechnology sector continues to face headwinds amid volatile market conditions. The India VIX index reached a new 52-week high today, signalling elevated market volatility. This environment has contributed to cautious investor sentiment across the sector, impacting stock prices including that of Procter & Gamble Health Ltd.
The company’s stock price decline is also reflective of broader market trends, with the Sensex experiencing a three-week consecutive fall and trading below key moving averages. These factors have compounded pressure on the stock’s valuation and price levels.
Summary of Key Metrics
To summarise, Procter & Gamble Health Ltd’s stock has declined to Rs.4781, its lowest level in 52 weeks, amid a challenging market backdrop and subdued growth metrics. The company’s financial results show a mixed picture, with profit growth contrasting with recent quarterly declines. Valuation remains elevated relative to earnings and book value, while dividend yield offers some income appeal. Institutional ownership and strong management efficiency provide stability, though the stock’s recent performance reflects ongoing pressures within the sector and market.
Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today
